Affiliation:
1. Northern State Medical University, Russian Ministry of Health
Abstract
The objective: to evaluate results of M. tuberculosis detection and testing drug susceptibility to rifampicin using molecular genetic methods in tuberculosis patients with a negative sputum smear microscopy result.Subjects and Methods. Pulmonary tuberculosis patients registered in Arkhangelsk Region from 2016 to 2020 were enrolled in the study; those patients were notified as new cases and relapses with a negative sputum smear microscopy result before treatment and had results of molecular genetic testing (MGT) (Xpert MTB/RIF MTB/RIF) and BACTEC MGIT 960 available.Results. 479 people (40%) were registered as pulmonary tuberculosis cases with a negative sputum smear microscopy result. MGT was performed in 327 (68%) patients. A positive result of MGT was received in 120 (37%) patients, a positive result of BACTEC MGIT 960 was received in 165 (50%) people. Concordance of results was observed in 70% of cases. In 136 (41%) people, both tests did not detect Mycobacterium tuberculosis, in 95 (29%) both tests showed a positive result. Discrepancies between the results of two tests were observed in 30% of cases. In 71 (22%) cases, culture growth was observed in BACTEC MGIT 960 with negative results of MGT. In 8% of cases, DNA of Mycobacterium tuberculosis was detected, but there was no culture growth on the nutrient medium. 43/120 (36%) cases of resistance to rifampicin were detected. The median time from sputum collection to initiation of MDR-TB treatment based on sputum MGT results made 18 (IQR 10–29) days. Molecular genetic testing makes it possible to promptly detect the majority of TB patients with a negative sputum smear result, and reduce the time for drug susceptibility testing, which allows this testing to be used as the first test when examining for pulmonary TB.
Publisher
LLC "Medical Knowledge and Technologies"
Reference24 articles.
1. Andreevskaya S.N., Smirnova T.G., Larionova E.E. et al. Comparison of XPERT MTB/RIF cartridge technology with microbiological methods for the detection of Mycobacterium tuberculosis and drug susceptibility testing. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2013, no. 2, pp. 25-29. (In Russ.)
2. Borodulina E.A., Shubina A.T., Gerasimov A.N. et al. GX technologies for rapid diagnosis of tuberculosis in general healthcare network. Vestnik Sovremennoy Klinicheskoy Meditsiny, 2022, vol. 15, no. 1, pp. 7-16. (In Russ.)
3. Vasilyeva I.A., Balasanyants G.S., Borisov S.E. et al. Tuberkulez u vzroslykh. Federal klinicheskie rekomendatsii. [Tuberculosis in adults. Federal guidelines]. Moscow, 2022. Available: https://cr.minzdrav.gov.ru/recomend/16_2 Accessed December 23, 2023.
4. Guseynalieva N.V. Improved detection of tuberculosis in primary health care and its impact on the incidence. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 10, pp. 41-46. (In Russ.)
5. Eliseev P.I., Detjen A., Dacombe R. et al. Impact of molecular genetic methods on the initiation of chemotherapy in multiple drug resistant tuberculosis patients in Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, vol. 95, no. 12, pp. 10-17. (In Russ.)